The study, conducted in a mouse model of glaucoma, demonstrates that administration of rhNGF protects retinal ganglion cells from degeneration and preserves visual function. Crucially, the investigators did not stop at showing that the treatment worked; they dissected the mechanisms underlying the benefit, revealing that rhNGF counteracts two intertwined drivers of glaucomatous damage—oxidative stress and neuroinflammation. This dual action positions nerve growth factor not merely as a survival signal for ailing neurons, but as a molecular shield against the hostile retinal environment that develops as the disease progresses.

Nerve growth factor was the first neurotrophin ever discovered, identified more than seventy years ago by Rita Levi-Montalcini and Stanley Cohen, work that earned the Nobel Prize in Physiology or Medicine in 1986. NGF is best known for its role in the development and maintenance of sympathetic and sensory neurons, but it also acts on the central nervous system, including the retina, where its receptors—TrkA and p75NTR—are expressed by retinal ganglion cells and by glial cells such as Müller cells and astrocytes. Over the years, evidence has accumulated that NGF signaling can promote neuronal survival, yet translating that biology into a practical therapy has been difficult, in part because delivering protein drugs to target tissues is challenging and because earlier clinical efforts were hampered by formulation and delivery limitations.

In the glaucoma model used in the study, elevated intraocular pressure triggers a cascade of degenerative events in the retina. Pressure insult compromises axonal transport at the optic nerve head, deprives ganglion cells of trophic support, and sets off a vicious cycle in which stressed neurons release damage signals that activate glial cells. Activated microglia and macroglia, in turn, release pro-inflammatory cytokines such as TNF-alpha and interleukin-1 beta and generate reactive oxygen species, further injuring neurons and perpetuating the inflammatory loop. The result is progressive loss of retinal ganglion cells, thinning of the nerve fiber layer, and deterioration of the visual responses that these cells convey to the brain.

When the researchers administered rhNGF to the glaucomatous mice, they observed a marked preservation of retinal structure and function compared with untreated animals. Histological analysis revealed significantly higher survival of retinal ganglion cells, and functional assessments of the visual pathway confirmed that the anatomical protection translated into preserved vision-related output. The magnitude of the effect indicates that rhNGF does not merely delay degeneration marginally but provides substantive neuroprotection in this experimental setting.

The mechanistic findings are arguably the most significant contribution of the work. Molecular analyses of treated retinas showed a pronounced reduction in markers of oxidative stress. Levels of reactive oxygen species and lipid peroxidation products fell, while endogenous antioxidant defenses were bolstered. This matters because oxidative damage is now recognized as a central pillar of glaucoma pathobiology: the retina is one of the most oxygen-demanding tissues in the body, its ganglion cell mitochondria are exceptionally vulnerable, and oxidative modifications to proteins, lipids, and DNA accumulate early in the disease and correlate with neuronal loss. By damping oxidative injury, rhNGF appears to interrupt one of the key upstream triggers of the degenerative cascade.

Equally important was the effect on neuroinflammation. In untreated glaucomatous retinas, the researchers documented robust activation of microglia—the resident immune cells of the retina and optic nerve—along with elevated expression of inflammatory cytokines. In rhNGF-treated animals, microglial activation was substantially attenuated and the inflammatory signature was blunted. This anti-inflammatory action is notable because it suggests that NGF signaling, in addition to its classical trophic role, actively reprograms the glial response to injury. The TrkA receptor, when engaged by NGF, can activate survival pathways such as PI3K-Akt and MAPK signaling in neurons, while modulating the reactivity of glial cells that would otherwise amplify tissue damage. The study’s data indicate that both dimensions of NGF biology—direct neuronal support and immunomodulation—contribute to the observed protection.

The interplay between oxidative stress and inflammation is what makes these findings particularly compelling. These two processes are not independent; reactive oxygen species can activate inflammatory signaling pathways, including the NF-kappaB and inflammasome pathways, and inflammatory cells are themselves major producers of free radicals. In glaucoma, this creates a self-reinforcing spiral in which each process feeds the other. A therapy that targets only one arm of the spiral may achieve limited benefit, whereas an intervention that simultaneously reduces oxidative damage and suppresses neuroinflammation can potentially break the cycle. The rhNGF results suggest that the molecule does precisely that, which may explain why the neuroprotection achieved in the mouse model was so robust.

The therapeutic implications extend beyond the laboratory. Recombinant human NGF has already navigated part of the translational path: a topical ocular formulation of rhNGF has been approved in Europe for the treatment of neurotrophic keratitis, a disease of corneal nerve degeneration, providing clinical precedent for the safety and feasibility of delivering this protein to the eye. The new findings raise the prospect of repurposing or reformulating rhNGF for glaucoma, potentially as an adjunct to pressure-lowering therapy. Such a combination would address both sides of the disease: intraocular pressure as the major modifiable risk factor, and the downstream neurodegenerative processes that pressure control alone cannot fully halt. For the millions of patients who continue to progress despite adequate pressure management, a neuroprotective add-on would represent a genuine paradigm shift.

Significant work remains before rhNGF can be considered a glaucoma therapy. The current evidence comes from an animal model, and mouse glaucoma models, while informative, do not capture every feature of the human disease, which unfolds over decades rather than weeks. Questions of dosing, delivery route, treatment timing, and long-term safety will need to be answered, and results will need to be replicated in additional models and ultimately in clinical trials. Nevertheless, the study provides a rigorous mechanistic foundation for the idea that nerve growth factor can protect the optic nerve in glaucoma, and it identifies oxidative stress and neuroinflammation as tractable, druggable targets. If the neuroprotective efficacy observed in mice can be reproduced in patients, rhNGF could become one of the first treatments in ophthalmology to preserve vision not by lowering pressure, but by directly defending the neurons that make sight possible.

Subject of Research: Neuroprotective efficacy of recombinant human nerve growth factor in a mouse model of glaucoma

Article Title: rhNGF shows neuroprotective efficacy by counteracting oxidative stress and neuroinflammation in a glaucoma mouse model

Article References: Vecchiotti, D., Di Vito Nolfi, M., Compagnoni, C., Miscione, M. S., Verzella, D., D’Andrea, D., Flati, I., Galli, F., d’Angelo, M., Angelucci, A., Cattani, F., Cimini, A., Tessitore, A., Capece, D., Alesse, E., Allegretti, M., & Zazzeroni, F. (2026). rhNGF shows neuroprotective efficacy by counteracting oxidative stress and neuroinflammation in a glaucoma mouse model. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03345-y

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03345-y

Keywords: glaucoma, rhNGF, nerve growth factor, neuroprotection, oxidative stress, neuroinflammation, retinal ganglion cells, intraocular pressure, microglia, optic nerve, TrkA receptor, Cell Death Discovery

The findings carry broad implications for male reproductive biology, inflammatory infertility research, and the fundamental question of how a highly specialized cell reprograms or discards the standard machinery of programmed cell death. Spermatozoa are transcriptionally silent cells. Once released from the testis and matured in the epididymis, they can no longer produce new proteins, synthesize DNA, or regulate their own gene expression. This limitation makes them an exceptional model for understanding which components of the apoptotic apparatus survive in a cell that has essentially frozen its molecular inventory.

To investigate how sperm respond to inflammatory conditions, the researchers exposed mature human sperm samples to TNF-α under controlled laboratory conditions and then assessed hallmarks of apoptosis, including phosphatidylserine externalization, mitochondrial membrane potential, caspase activation, and DNA fragmentation. In most somatic cells, binding of TNF-α to TNFR1 initiates a cascade: the receptor trimerizes, recruits the adaptor protein TRADD, and assembles a multiprotein complex known as Complex I. From there, signaling branches toward survival via NF-κB activation or toward death through Complex II and caspase-8, which in turn activates the executioner caspases-3 and -7.

In the sperm cells, however, this cascade appeared to stall at a very early stage. The study found that although TNFR1 is present on the sperm surface and can bind TNF-α, the downstream signaling that normally follows receptor engagement is functionally incomplete. The adaptor proteins required to transmit the death signal are either absent, sequestered, or otherwise nonfunctional in the mature gamete. Without a competent signalosome, the receptor behaves largely as a passive binding site rather than an active trigger of apoptosis.

The authors describe this phenomenon as TNFR1-associated apoptotic resistance. In essence, the receptor’s presence creates a misleading impression: the cell appears equipped to respond to TNF-α, but the molecular wiring behind the receptor has been dismantled during spermiogenesis. This is a biologically coherent outcome. During the dramatic remodeling that converts a round spermatid into a streamlined sperm cell, most of the cytoplasm is discarded, along with the organelles and protein pools that somatic cells rely upon for signaling. What remains is a compact, highly specialized cell optimized for delivery of the paternal genome, not for orchestrating complex signaling conversations with its environment.

Importantly, the resistance was not absolute or indiscriminate. The researchers found that sperm could still undergo forms of cell death, but these appeared to proceed through pathways that do not depend on the canonical TNFR1-driven route. Mitochondrial dysfunction, oxidative stress, and membrane damage can all compromise sperm function and viability, and these stressors operate independently of the receptor pathway. The distinction matters clinically: it suggests that inflammatory conditions rich in TNF-α, such as those seen in male reproductive tract infections, may impair fertility through mechanisms other than classic apoptosis, for example by damaging membranes, disrupting the acrosome, or generating reactive oxygen species.

The implications extend to assisted reproduction as well. Semen processing techniques, sperm selection methods, and culture conditions all expose gametes to variable inflammatory and oxidative environments. Understanding that mature sperm are intrinsically resistant to TNF-α-mediated apoptosis clarifies why simply bathing sperm in inflammatory cytokines does not selectively eliminate damaged cells through this route, a consideration that could inform future sperm selection strategies designed to enrich for the healthiest subpopulations. If TNFR1 signaling is inert, then therapeutic or diagnostic approaches that assume its functionality in sperm need to be reconsidered.

From an evolutionary perspective, apoptotic resistance in the mature gamete raises fascinating questions. On one hand, insensitivity to inflammatory death signals could protect sperm during their transit through tissues that are sometimes inflamed, allowing them to reach the oocyte even under hostile conditions. On the other hand, some scientists have argued that apoptosis-like changes in sperm serve as a quality control mechanism, marking defective cells for removal. The new findings suggest that this quality control, if it exists in mature sperm, does not operate through the TNFR1 axis, pointing instead to other regulators that remain to be fully characterized.

The study also adds to a growing literature on death receptor signaling in germ cells. Earlier work established that immature germ cells express functional death receptors and can respond to Fas ligand and TNF family cytokines, and that this responsiveness diminishes as cells mature. The present work sharpens that picture by demonstrating, with modern flow cytometric, biochemical, and functional assays, that the block in mature sperm occurs at the level of receptor-proximal complex assembly rather than at the death execution machinery itself. In other words, some executioner components persist in the gamete, but the ignition switch that would engage them has been disconnected.

Looking ahead, the researchers suggest several directions for follow-up work. Characterizing exactly which adaptor proteins are lost or inactivated during spermiogenesis, determining whether any residual TNFR1 signaling influences sperm motility or fertilization capacity through non-apoptotic routes, and testing whether similar resistance mechanisms operate in sperm of other species are all natural next steps. There is also therapeutic potential: if the mechanisms that confer apoptotic resistance can be understood in molecular detail, they might inspire strategies to protect somatic cells from inflammatory death in conditions such as sepsis or neurodegeneration, or conversely, to sensitize unwanted cells to TNF-α. For now, the study stands as an elegant demonstration that even the most fundamental programs of cell biology are not universal, and that the human spermatozoon, in its stripped-down simplicity, has rewritten the rules of the death receptor pathway to suit its singular purpose.

Subject of Research: TNFR1-mediated apoptotic resistance in mature human spermatozoa exposed to TNF-α

Article Title: TNFR1-associated apoptotic resistance in mature human spermatozoa under TNF-α exposure

Article References: Barbonetti, A., Tonni, C., Donatelli, V., Castellini, C., Moretto, C., Tienforti, D., Augello, F. R., Cinque, B., & Palumbo, P. (2026). TNFR1-associated apoptotic resistance in mature human spermatozoa under TNF-α exposure. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03355-w

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03355-w

Keywords: TNFR1, TNF-α, apoptosis, human spermatozoa, male fertility, Cell Death Discovery, death receptor signaling, sperm selection, inflammatory cytokines, spermiogenesis, caspases, assisted reproduction

Osteocytes are the most abundant cells in bone, making up roughly ninety percent of all bone cells, and they orchestrate the constant remodeling dialogue between bone formation and bone resorption. When glucocorticoid excess strikes, trabecular bone—the spongy lattice inside vertebrae and the ends of long bones—suffers the most visible early damage. But clinicians have long observed that cortical bone, the compact shell that provides most of the skeleton’s strength, also deteriorates under prolonged steroid exposure, and that this cortical thinning correlates strongly with nonvertebral fractures. The new research provides a mechanistic account of how the cells inside cortical bone are driven to self-destruction and how their demise translates directly into mineral loss from the surrounding matrix.

The investigative team used a well-established mouse model of glucocorticoid-induced osteoporosis, in which animals receive chronic prednisolone or methylprednisolone treatment sufficient to reproduce the human pattern of rapid bone loss. Using histomorphometry, micro-computed tomography, and dynamic bone labeling, they documented substantial cortical porosity, cortical thinning, and loss of mechanical integrity. Strikingly, the loss was accompanied by a marked depletion of osteocytes within the cortical compartment and by empty lacunae—minute cavities that once housed living cells—scattered throughout the cortex. This pattern suggested that osteocyte death itself, rather than merely elevated resorption by the classic bone-dissolving osteoclasts, might be a primary event in the pathology.

To define the mode of osteocyte death, the researchers examined the molecular machinery of necroptosis, a form of regulated necrosis distinguished from apoptosis by its explosive, membrane-rupturing character and its capacity to release intracellular contents that inflame surrounding tissue. Necroptosis is executed by a signaling complex in which receptor-interacting protein kinase 1 and receptor-interacting protein kinase 3 activate the executioner protein mixed lineage kinase domain-like pseudokinase, or MLKL, which oligomerizes and punches holes in the cell membrane. In the steroid-treated mice, the team found robust activation of this pathway specifically in cortical osteocytes: phosphorylated RIPK3 and phosphorylated MLKL accumulated within lacunar cells, while markers of apoptosis were comparatively modest. Genetic or pharmacological interference with the pathway therefore became the decisive test of causality.

When the researchers crossed their glucocorticoid-treated mice with animals lacking functional MLKL, or when they treated mice with a selective RIPK1 kinase inhibitor, the picture changed dramatically. Cortical bone loss was substantially attenuated: cortical thickness was preserved, porosity declined, and biomechanical testing showed that bones retained significantly more of their strength compared with steroid-treated controls carrying intact necroptosis machinery. Osteocyte lacunae remained populated, and the hallmarks of inflammatory cell death faded. Inhibiting apoptosis, by contrast, produced only modest skeletal protection, reinforcing the conclusion that necroptosis is the dominant death program through which glucocorticoids destroy the osteocyte network in cortical bone.

The most provocative element of the study is the mechanism the authors propose for how dying osteocytes cause resorption of the mineral that surrounds them. Under normal physiological conditions, osteocytes can participate in a process called osteocytic osteolysis, in which stressed or starved osteocytes demineralize and degrade their own perilacunar matrix, releasing calcium and remolding their immediate microenvironment. The study demonstrates that necroptotic death converts this finely regulated process into a destructive free-for-all. As necroptotic osteocytes rupture, they release damage-associated molecular patterns and lysosomal enzymes that acidify the perilacunar space and dissolve the adjacent mineralized collagen matrix. In essence, each dying cell excavates the bone around it, generating the microscopic porosity that, when multiplied across millions of lacunae, hollows out the cortex from within.

Supporting this mechanism, the researchers tracked perilacunar remodeling with dynamic imaging and found that steroid exposure dramatically expanded the demineralized halos around individual lacunae, a signature of aggressive osteocytic osteolysis. They also showed that products released from necroptotic osteocytes could recruit and activate osteoclast precursors, coupling the internal excavation to conventional resorption on bone surfaces. This dual mechanism—autolytic matrix degradation by the dying cells themselves followed by secondary osteoclast activation—offers a coherent explanation for the peculiar severity and speed of glucocorticoid-induced cortical loss, which has never been fully accounted for by osteoclast activity alone.

The clinical implications are considerable. Current management of glucocorticoid-induced osteoporosis relies on calcium and vitamin D supplementation and antiresorptive agents such as bisphosphonates, which dampen osteoclast function but do nothing to protect osteocytes from dying. If necroptosis inhibition shields osteocytes from steroid toxicity in humans as it does in mice, a fundamentally new class of preventive therapy becomes conceivable: drugs that preserve the cellular network inside bone, maintaining the mechanosensory and regulatory functions that keep remodeling balanced, while simultaneously stemming the perilacunar erosion that undermines cortical strength. Inhibitors targeting the RIPK1–RIPK3–MLKL axis are already in clinical development for inflammatory and neurodegenerative diseases, which could accelerate translation into skeletal medicine.

The authors are careful to frame their conclusions within the limits of the model system. Necroptosis is a context-dependent process, and its contribution to bone loss may vary with dose, duration of steroid exposure, age, and species. Human bone biopsies from patients on long-term glucocorticoid therapy will be needed to confirm that the same molecular signature of phosphorylated MLKL and perilacunar demineralization appears in cortical osteocytes in vivo. Nonetheless, the convergence of genetic, pharmacological, and structural evidence in this study provides an unusually complete causal chain, linking a specific cell death program to a specific mode of matrix destruction and to a measurable functional outcome in the skeleton.

Beyond the immediate therapeutic horizon, the work reframes how scientists think about the skeleton’s response to stress. Osteocytes, once viewed as inert placeholders, are now firmly established as the command centers of bone, and their death by necroptosis represents a catastrophic failure of that command infrastructure. The finding that the same cells whose death is triggered by steroid excess then participate in dismantling their own mineralized surroundings blurs the boundary between cell death and bone resorption, suggesting that in disease states the two processes are woven together. For the millions of patients worldwide who depend on glucocorticoids, the study offers a concrete molecular target for keeping their skeletons intact—and a reminder that some of the most important cells in bone are the ones buried deepest inside it.

Subject of Research: Necroptosis of osteocytes as a mechanism of cortical bone resorption in glucocorticoid-induced osteoporosis

Article Title: Osteocyte necroptosis drives cortical bone resorption via osteocytic osteolysis in glucocorticoid-induced osteoporosis

Article References: Osteocyte necroptosis drives cortical bone resorption via osteocytic osteolysis in glucocorticoid-induced osteoporosis. (n.d.). https://doi.org/10.1038/s41420-026-03329-y

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03329-y

Keywords: osteocytes, necroptosis, glucocorticoid-induced osteoporosis, cortical bone, osteocytic osteolysis, MLKL, RIPK3, bone resorption, osteoclasts, perilacunar remodeling, Cell Death Discovery, bone fractures

EMT is a fundamental developmental program that is hijacked in cancer. During EMT, cells lose the apical-basal polarity and cell-cell adhesion molecules, such as E-cadherin, that hold epithelial sheets together, and they instead express mesenchymal markers including N-cadherin, vimentin, and transcriptional repressors of the Snail, Slug, Twist, and Zeb families. In lung biology, this program is deeply implicated in both pathological fibrosis and carcinoma progression, since the same signaling cascades that mobilize epithelial plasticity during wound repair can be co-opted by tumor cells to detach, migrate, invade surrounding tissue, and ultimately seed metastases. Transforming growth factor beta, or TGF-β, is the most potent and widely studied inducer of EMT, activating downstream SMAD-dependent transcription as well as non-canonical pathways involving MAPK, PI3K-AKT, and Rho GTPases.

What has become increasingly clear over the past decade is that EMT is not merely a change in gene expression; it is a wholesale reorganization of cellular metabolism. Epithelial cells, which rely heavily on mitochondrial oxidative phosphorylation to generate ATP, must rewire their energetic machinery to support the demanding biosynthetic needs of a migrating, proliferating cell. Aerobic glycolysis provides rapid ATP and, critically, diverts glycolytic intermediates into branching anabolic pathways, including the pentose phosphate pathway for nucleotide synthesis and serine biosynthesis routes for lipid and amino acid generation. This metabolic flexibility is thought to be a prerequisite for successful EMT rather than simply a byproduct of it, and teasing apart cause from consequence is precisely the challenge that the new work addresses.

The research team focused on lung epithelial cells because the lung represents a clinical arena in which EMT-linked processes carry enormous weight. Idiopathic pulmonary fibrosis involves fibroblast activation and epithelial cell state transitions driven in part by TGF-β, while lung cancers, including non-small cell lung carcinoma, frequently display hybrid epithelial-mesenchymal phenotypes associated with drug resistance and metastatic spread. Understanding whether glycolytic reprogramming is a driver or a passenger in the TGF-β-induced transition of lung epithelial cells therefore has implications that extend from basic cell biology to therapeutic strategy, because metabolic enzymes are, in principle, druggable targets in a way that master transcription factors often are not.

Technically, the investigation combined TGF-β stimulation of lung epithelial cell models with measurements of glycolytic flux, lactate production, and the expression of key glycolytic enzymes such as hexokinase 2, phosphofructokinase, and lactate dehydrogenase A. These functional readouts were integrated with assessments of EMT marker expression, including the loss of E-cadherin and the gain of vimentin and N-cadherin, to establish a temporal and causal relationship between metabolic shift and phenotypic conversion. Such paired metabolic and molecular phenotyping is essential because TGF-β is known to alter numerous cellular processes simultaneously, and only carefully timed interventions can reveal which changes are required for EMT to proceed and which are secondary consequences of it.

The broader literature supports the plausibility of a causal link. Hypoxia-inducible factor 1 alpha, a master regulator of glycolytic gene expression, is stabilized not only by low oxygen but also by TGF-β signaling through mechanisms involving reactive oxygen species and mTOR pathway activation. At the same time, TGF-β suppresses the expression of PPAR gamma coactivator 1 alpha, a key driver of mitochondrial biogenesis, thereby tilting the balance away from oxidative metabolism. Glycolytic enzymes themselves have been reported to moonlight as transcriptional co-regulators; for example, certain glycolysis-associated factors can influence the activity of EMT transcription factors, creating feedback loops in which metabolism and gene expression reinforce one another. If such loops operate in lung epithelial cells, blocking glycolysis could potentially arrest or reverse the EMT program rather than merely slowing cellular energy production.

Therapeutically, the implications are considerable. Drugs that target glycolysis, ranging from hexokinase inhibitors to lactate dehydrogenase inhibitors, have been explored in preclinical cancer models for years, although clinical translation has been complicated by the dependence of normal tissues, including the brain and red blood cells, on glucose metabolism. The value of the new work lies in narrowing the therapeutic window: if glycolytic dependency is specifically induced during the EMT transition in lung epithelial cells, then transient metabolic intervention could be timed to coincide with windows of tumor plasticity, such as during the emergence of resistance to targeted therapies or immune checkpoint inhibitors, when EMT-associated states are thought to be most prominent.

The study also speaks to a conceptual shift in how the field understands cell state transitions. EMT is now recognized not as a binary switch but as a spectrum of hybrid states, with cells occupying partial epithelial-mesenchymal phenotypes that may be particularly aggressive and drug tolerant. Metabolic profiling adds an additional axis to this landscape: hybrid cells may display intermediate glycolytic dependency, fully mesenchymal cells may be the most glycolytic, and reversibility of the process may depend on whether the metabolic reprogramming has been consolidated through epigenetic modification. Stable chromatin changes at EMT gene loci could lock in a mesenchymal state even after the original TGF-β signal dissipates, suggesting that metabolic interventions would need to occur early in the transition to be effective.

For patients with lung disease, the distance between mechanistic cell biology and clinical benefit remains substantial, and the authors’ findings should be understood as foundational rather than immediately actionable. Nevertheless, the convergence of TGF-β biology, metabolic reprogramming, and epithelial plasticity in lung cells offers a coherent framework for developing biomarkers that identify patients whose tumors or fibrotic lesions are undergoing active EMT, and for designing combination regimens in which metabolic inhibitors sensitize cells to existing TGF-β pathway antagonists, kinase inhibitors, or antifibrotic agents. As the field continues to map the metabolic architecture of cell state transitions, studies like this one bring the goal of intervening in cancer progression and fibrosis at the level of cellular identity, rather than merely cellular proliferation, steadily closer to realization.

Subject of Research: The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells

Article Title: The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells

Article References: Huang, S.-W., Chen, H.-C., Peng, S.-Y., Chuang, C.-H., Chen, B.-C., Cheng, W.-H., Cools, J. M. T., Neoh, M.-M., Hsiao, S.-H., & Hsu, M.-J. (2026). The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03322-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03322-5

Keywords: aerobic glycolysis, Warburg effect, TGF-beta, epithelial-to-mesenchymal transition, lung epithelial cells, EMT, cancer metastasis, metabolic reprogramming, lactate dehydrogenase, pulmonary fibrosis, cell death discovery, glycolytic flux

The significance of the finding lies in its dual mechanism. Cardiovascular researchers have traditionally treated endothelial dysfunction and macrophage-driven inflammation as related but distinct strands of the atherosclerosis story. The endothelium, a single-cell-thick lining that governs vascular tone, barrier integrity, and leukocyte trafficking, is often the first casualty of cardiovascular risk factors such as hypertension, hyperlipidemia, and diabetes. When endothelial cells malfunction, they express fewer protective molecules such as nitric oxide and more adhesion molecules that invite circulating monocytes to breach the vessel wall. Meanwhile, once inside the intima, monocytes differentiate into macrophages that gorge on oxidized lipids, transform into foam cells, and release a cascade of inflammatory cytokines that amplify lesion growth. The new work suggests that PLCE1 is a single upstream node that helps orchestrate both of these pathological processes at once.

PLCE1 encodes an enzyme belonging to the phospholipase C family, proteins that cleave the membrane phospholipid PIP2 into two potent second messengers, inositol trisphosphate and diacylglycerol. These messengers mobilize intracellular calcium and activate protein kinase C, triggering a wide range of cellular responses. PLCE1 is unusual among phospholipases because it also carries a Ras-associating domain and a Ras-GEF domain, linking it directly to small GTPase signaling pathways that control cell proliferation, migration, and survival. Genetic studies over the past decade and a half have repeatedly flagged variants within the PLCE1 gene locus in genome-wide association studies of coronary artery disease, and even earlier of stroke risk in some populations. What those association studies could not resolve was whether PLCE1 is merely a bystander genetically linked to true disease drivers, or an active participant in the disease process. The new findings argue firmly for the latter.

Using a combination of cellular models, animal experiments, and mechanistic analyses, the research team demonstrated that elevated PLCE1 activity worsens endothelial dysfunction. In endothelial cells, increased PLCE1 expression was associated with impaired endothelial function markers, disturbed barrier behavior, and a shift toward the pro-inflammatory, pro-adhesive state that characterizes early lesion formation. When the investigators suppressed PLCE1 in experimental models of atherosclerosis, the resulting lesions were less severe, and the endothelial lining displayed healthier functional characteristics. This directional evidence, that manipulation of PLCE1 changes disease severity rather than simply tracking with it, is the kind of causal data that genetic association studies alone can never provide.

The second arm of the mechanism concerns macrophages, the immune workhorses whose transformation into lipid-laden foam cells defines the atherosclerotic plaque. The study found that PLCE1 promotes a pro-inflammatory phenotype in macrophages, driving the production and release of inflammatory mediators that recruit further immune cells and destabilize plaques. Macrophage inflammation is now recognized as a central engine of atherosclerotic progression, a view powerfully validated by the landmark CANTOS clinical trial, which showed that directly targeting the inflammatory cytokine IL-1 beta reduces cardiovascular events independently of cholesterol lowering. By implicating PLCE1 upstream of macrophage inflammatory activation, the new research adds a candidate control point that could, in principle, restrain this inflammatory engine at its source.

The most consequential discovery, however, may be the identification of CTNNB1 as the molecular target linking PLCE1 to both pathologies. CTNNB1 encodes beta-catenin, the central transducer of the canonical Wnt signaling pathway and a transcriptional co-regulator with its finger in countless developmental and inflammatory processes. In the study’s experimental framework, PLCE1 was shown to act on beta-catenin signaling, and beta-catenin in turn mediated the downstream effects on endothelial cells and macrophages. When beta-catenin was experimentally depleted, the harmful consequences of PLCE1 overexpression were blunted. This epistatic relationship, in which removing the target abolishes the effect of the driver, is a classic hallmark of a genuine signaling axis, and it suggests a linear pathway: PLCE1 acts upon beta-catenin, and beta-catenin drives the gene expression programs that produce endothelial dysfunction and macrophage inflammation.

This proposed axis is biologically plausible in light of prior literature. Beta-catenin signaling has been repeatedly implicated in vascular inflammation, with Wnt-beta-catenin activity reported to increase endothelial permeability and to promote inflammatory gene expression in both endothelial cells and macrophages under atherosclerotic conditions. What the new study contributes is the placement of PLCE1 upstream of this pathway in the specific context of arterial disease, transforming scattered mechanistic hints into a coherent, testable model. It also offers a potential explanation for longstanding genetic associations between PLCE1 variants and cardiovascular outcomes: those variants may alter the intensity of beta-catenin signaling in the vessel wall, tuning the inflammatory set point of atherosclerotic tissue.

From a therapeutic standpoint, the findings are provocative but must be tempered by important caveats. Both PLCE1 and beta-catenin are pleiotropic molecules, meaning they perform essential functions far beyond the vascular system. Beta-catenin, in particular, is indispensable for stem cell maintenance in the intestine, bone formation, and a host of developmental processes, which is why systemic Wnt-pathway inhibitors have repeatedly stumbled in cancer trials due to toxicity. Any attempt to translate the PLCE1-beta-catenin axis into a cardiovascular therapy would almost certainly require highly targeted delivery, perhaps to vascular endothelium or lesional macrophages, or the identification of downstream effectors that are more vascular-specific. The study does not itself report a candidate drug or clinical intervention, and its conclusions rest on experimental models whose fidelity to human atherosclerosis, while substantial, is never complete.

Nevertheless, the work exemplifies a broader and encouraging trend in cardiovascular biology: the convergence of human genetics, molecular signaling, and immunology into unified mechanistic accounts of atherosclerosis. For decades, the field’s therapeutic triumphs came almost exclusively from lipid metabolism, embodied by statins and more recently PCSK9 inhibitors. Yet a large residual risk persists in patients whose cholesterol is well controlled, and that residual burden is increasingly attributed to inflammation and vascular dysfunction. Identifying molecules like PLCE1 that couple inflammatory and endothelial pathologies through a defined signaling route gives researchers exactly the kind of targets needed to address this residual risk. It also enriches the interpretation of existing genetic risk scores, which currently aggregate thousands of variants of unknown function. Each variant that is functionally resolved, as PLCE1 variants now partly are, converts statistical prediction into biological insight.

For now, the immediate value of the study lies in its demonstration of a principle: that a single enzyme can coordinate two of the most destructive processes in atherosclerosis through a well-defined molecular partner. Future work will need to confirm the PLCE1-beta-catenin axis in human tissue, map precisely how PLCE1 activity modifies beta-catenin at the molecular level, and determine whether existing or novel pharmacological tools can safely modulate this pathway in patients at risk. If those steps succeed, a gene discovered through population association studies may finally graduate from statistical curiosity to therapeutic target, offering a new angle of attack on the world’s leading cause of death. In a disease as complex and multifactorial as atherosclerosis, every newly charted junction in the signaling map is a potential checkpoint at which progression might be halted, and PLCE1 has just been added to that map in bold.

Subject of Research: The role of PLCE1 in driving atherosclerosis through endothelial dysfunction and macrophage inflammation via CTNNB1

Article Title: PLCE1 exacerbates the development of atherosclerosis by driving endothelial dysfunction and macrophage inflammation via targeting CTNNB1

Article References: Cheng, W.-L., Shi, Y., Zhang, Q., Cai, Z., Jiang, F.-X., Kong, X., Cao, J.-L., Peng, L., Chen, M., He, T., & Wang, H. (2026). PLCE1 exacerbates the development of atherosclerosis by driving endothelial dysfunction and macrophage inflammation via targeting CTNNB1. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03309-2

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03309-2

Keywords: PLCE1, atherosclerosis, CTNNB1, beta-catenin, endothelial dysfunction, macrophage inflammation, cardiovascular disease, Cell Death Discovery, Wnt signaling, foam cells, heart disease, molecular mechanism

CD19 has become the single most important target in B-cell malignancy therapy. Chimeric antigen receptor T-cell therapies, bispecific antibodies, and antibody-drug conjugates overwhelmingly depend on the dense, consistent expression of CD19 on the surface of malignant B lymphocytes. Yet relapse after CD19-directed immunotherapy is common, and one of the best-documented mechanisms of that relapse is the loss or masking of surface CD19. Tumor cells that downregulate the antigen effectively become invisible to the therapy, resuming their growth once the immune pressure has been evaded. Understanding what controls CD19 abundance at the cell surface, and how clinical drugs might stabilize it, is therefore a question of substantial therapeutic consequence. The new work addresses that question directly, and its answer involves an unlikely player.

Matriptase, encoded by the ST14 gene, is a type II transmembrane serine protease with a well-established role in epithelial biology. It is best known for initiating proteolytic cascades that regulate barrier function, filaggrin processing, and growth factor signaling in skin and other epithelial tissues. Its dysregulation has been implicated in epithelial cancers, where excessive matriptase activity can promote invasion and metastasis. Its role in lymphoid malignancies, by contrast, has been far less explored. The new study now places matriptase at the center of a drug-responsive circuit in malignant B cells, where it appears to act on the fate of CD19 itself, preserving the antigen in its extracellular, antibody-accessible form rather than allowing it to be shed, internalized, or otherwise lost from the cell surface.

The central observation is a causal chain. When malignant B cells are exposed to ibrutinib, the drug does more than inhibit BTK signaling; it triggers an increase in matriptase activity or abundance. That protease, in turn, acts to maintain extracellular CD19. In practical terms, cells treated with the drug retain the surface target that CAR-T cells and CD19-directed antibodies recognize, whereas cells in which the matriptase arm of this circuit is disrupted lose that protection and become prone to antigen escape. The authors frame this as a mechanism by which ibrutinib limits antigen escape in B-cell malignancy, a framing that carries immediate translational weight because ibrutinib is already approved and widely used in chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell disorders.

The clinical logic of the finding is compelling. Ibrutinib and CD19-directed immunotherapies are frequently considered in overlapping patient populations, and sequencing decisions between BTK inhibition and cellular immunotherapy are often made empirically. If ibrutinib treatment stabilizes surface CD19, then a period of BTK inhibition before leukapheresis or CAR-T infusion could, in principle, improve the quality of the target presented to the engineered cells, reducing the likelihood that the manufactured product encounters antigen-low tumor cells. Conversely, the study raises a caution: interventions or tumor adaptations that suppress matriptase might undermine CD19 display and thereby predispose patients to escape from CD19-directed therapies, even when the malignant cells remain otherwise sensitive to cytotoxic pressure.

Antigen escape is not a single mechanism but a family of them. Tumor cells can mutate the CD19 locus, introduce truncating mutations, alter exon splicing so that the epitope is lost while the protein remains, internalize the antigen faster than it is replaced, or shield it from antibody binding through changes in the membrane microenvironment. Each of these routes has been documented in patients relapsing after CD19 CAR-T therapy. What the new study contributes is the idea that the extracellular maintenance of CD19 is an actively regulated process, one that a protease can influence and that an approved drug can modulate. That reframing matters because it converts antigen loss from an apparently random escape event into a process with identifiable molecular control points that might be monitored and manipulated.

The mechanistic details also connect two previously separate strands of B-cell biology. BTK signaling sits at the heart of the B-cell receptor pathway, and its chronic engagement is a hallmark of many B-cell malignancies, particularly those dependent on active B-cell receptor signaling such as chronic lymphocytic leukemia and mantle cell lymphoma. Ibrutinib’s inhibition of BTK disrupts survival signals and drives malignant cells toward apoptosis. The new data suggest that this well-characterized pharmacologic action has a second, previously underappreciated consequence: a protease-mediated remodeling of the tumor cell surface that favors target retention. In effect, a drug designed to weaken the tumor may simultaneously make the tumor easier to see for the immune system, an unintended benefit that could be exploited deliberately.

For researchers in the immunotherapy field, the study suggests several lines of immediate follow-up. Measuring matriptase activity in patient samples before CD19-directed therapy could reveal whether protease status predicts who is at risk of antigen-negative relapse. Pharmacologic or genetic modulation of matriptase in preclinical models could test whether enhancing its activity further improves CD19 persistence under immune pressure. Combination trials pairing ibrutinib with CD19 CAR-T or bispecific antibodies are already underway for various indications, and the new mechanism provides a biological rationale for such combinations that goes beyond simple additive cytotoxicity. Biomarker strategies that track surface CD19 density longitudinally during BTK inhibition could also help clinicians time cellular therapy infusions for maximal target availability.

There are, of course, important caveats. Matriptase is a protease with pleiotropic effects, and its activity in epithelial cancers has often been associated with tumor progression, so any therapeutic strategy aimed at boosting its function in lymphoid malignancy would need to account for tissue-specific context and potential off-tumor consequences. The relationship between ibrutinib exposure, matriptase activation, and CD19 maintenance will also need to be validated across the full diversity of B-cell malignancies, since the biology of chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma differ substantially in their dependence on BTK signaling and their patterns of antigen expression. Clinical outcomes, not only cell-culture measurements, will ultimately determine whether the mechanism translates into lower rates of antigen-escape relapse in treated patients.

Even with those qualifications, the study adds a genuinely new concept to the immunotherapy conversation: that the target itself can be pharmacologically defended. Much of the effort in overcoming antigen escape has focused on the therapeutic side, through multi-antigen CAR constructs targeting CD19 together with CD20 or CD22, or through sequential and dual-targeting strategies. The alternative approach suggested here is to act on the tumor cell so that it continues to display the antigen the therapy needs. If ibrutinib-triggered matriptase activity proves to be a reliable and safe lever for maintaining extracellular CD19, it would represent a rare example of an approved small-molecule drug being repurposed, at least conceptually, as a target-preservation agent for cellular immunotherapy. In a field where antigen loss remains one of the leading causes of treatment failure, that is an idea with the potential to reshape how BTK inhibitors and CD19-directed therapies are sequenced and combined in the clinic.

Subject of Research: Ibrutinib-triggered matriptase activity maintains extracellular CD19 and limits antigen escape in B-cell malignancy

Article Title: Ibrutinib-triggered matriptase maintains extracellular CD19 and limits antigen escape in B-cell malignancy

Article References: Lu, X.-J., Lai, H.-F., Hung, Y.-S., Wang, Y.-J., Wu, S.-C., Wang, J.-K., Wu, Y.-Y., & Chiu, Y.-L. (2026). Ibrutinib-triggered matriptase maintains extracellular CD19 and limits antigen escape in B-cell malignancy. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03306-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03306-5

Keywords: ibrutinib, matriptase, CD19, antigen escape, B-cell malignancy, BTK inhibitor, CAR-T therapy, immunotherapy, Cell Death Discovery, serine protease, chronic lymphocytic leukemia, target preservation

SUMOylation is the process by which small ubiquitin-like modifier proteins, or SUMOs, are covalently attached to target proteins inside the cell. Far from being a minor decoration, SUMOylation is a master regulator of protein behavior. By conjugating SUMO to transcription factors, chromatin modifiers, signaling proteins and structural components, cells can rapidly alter protein stability, subcellular localization, interaction partners and activity without synthesizing new proteins. The modification is reversible, dynamic and highly responsive to cellular stress, making it an ideal instrument for a tissue that must constantly adapt its gene expression program to changing demands.

Skeletal muscle depends on precisely this kind of coordinated control. Contractile function emerges from the orchestrated expression of myosin heavy chains, actin, troponins, calcium-handling machinery and mitochondrial proteins, all of which must be maintained in strict proportion. When the transcriptional architecture supporting this program falters, the consequences are not simply a loss of muscle mass but a qualitative decline in the muscle’s ability to generate force. This distinction matters clinically, because patients with cancer can lose contractile capacity even when the change in raw muscle volume appears modest.

The new research set out to map how this control system is perturbed when muscle is exposed to a cancer environment. Rather than asking only which genes change, the investigators asked which proteins carry SUMO marks, how the ensemble of SUMOylated proteins shifts, and how those shifts align with changes in transcriptional regulation. The resulting picture is one of global reorientation: the set of SUMOylated targets in cancer-affected muscle differs markedly from that in healthy tissue, implying that SUMO conjugation is redirected toward a new set of substrates as the disease progresses.

At the center of this reprogramming sits L3mbtl2, a member of the mbt-domain family of chromatin-binding proteins. L3mbtl2 functions as a transcriptional repressor, reading methylated histone marks through its mbt domains and helping assemble Polycomb-like repressive complexes that compact chromatin and silence target genes. In muscle, such chromatin-based repression is essential for maintaining fiber-type identity and preventing inappropriate activation of non-muscle programs. The study reports that the transcriptional activity mediated by L3mbtl2 is altered in the setting of cancer-associated contractile dysfunction, indicating that this epigenetic gatekeeper no longer holds its normal regulatory position.

The convergence of SUMOylation and L3mbtl2 is biologically compelling. SUMO modification is known to influence chromatin regulators directly, modulating their ability to bind DNA, recruit co-factors and establish repressive domains. A reoriented SUMOylation landscape could therefore change L3mbtl2’s behavior at chromatin, either by modifying the protein itself or by altering the availability of SUMO-dependent co-regulators in the complex. The net effect described in the paper is a transcriptional state in muscle that diverges from the healthy program, consistent with the observed contractile deficits.

Methodologically, the study exemplifies the current shift in muscle biology from single-readout measurements to systems-level profiling. Global SUMOylation mapping requires enrichment of SUMOylated proteins followed by mass spectrometric identification, an approach that captures hundreds of modified substrates in a single experiment. Aligning that map with transcriptomic data allows researchers to connect post-translational modifications to the gene expression outcomes they help produce. It is this integration that elevates the findings beyond a catalog of altered marks toward a mechanistic model of how cancer distorts muscle gene control.

The clinical implications are potentially significant. If SUMO pathway enzymes or L3mbtl2-dependent chromatin complexes can be shown to drive contractile dysfunction, they would represent a class of therapeutic targets fundamentally different from the nutritional and anti-inflammatory strategies that currently dominate cachexia management. Pharmacological modulation of SUMOylation is already an active area of research in oncology, with inhibitors of SUMO-activating enzyme under investigation for certain cancers. A clearer understanding of how these pathways behave in muscle could open the door to interventions that preserve muscle quality rather than merely slowing its loss, a goal that has remained elusive despite decades of effort.

There are, of course, important caveats. SUMOylation is ubiquitous, and systemic manipulation of the pathway carries risks, given its roles in genome stability, DNA repair and stress responses in virtually every tissue. Any therapeutic strategy would need to achieve tissue selectivity or be directed at a muscle-specific downstream effector such as the L3mbtl2 complex. Further work will also be needed to determine whether the reorientation of the SUMO landscape is a cause of contractile dysfunction or a consequence of it, and whether restoring normal SUMO patterns in preclinical models rescues muscle force output.

Even so, the study adds an important dimension to a growing recognition that epigenetic and post-translational mechanisms lie at the heart of cancer-associated muscle failure. The muscle wasting that shadows malignant disease has long been treated as a metabolic problem, a matter of energy balance and protein turnover. This work reframes it as a problem of information: cancer corrupts the chemical signals that tell muscle genes what to do, and the SUMOylation system, acting through chromatin regulators such as L3mbtl2, appears to be a key carrier of that corrupted message. Decoding that signal with greater precision may ultimately offer patients something that current supportive care cannot: the preservation not just of muscle mass, but of the strength to use it.

Subject of Research: SUMOylation reprogramming and L3mbtl2-mediated transcriptional changes in cancer-associated skeletal muscle contractile dysfunction

Article Title: Reorientation of the SUMOylation landscape and altered L3mbtl2-mediated transcriptional activity in cancer-associated muscle contractile dysfunction

Article References: Reorientation of the SUMOylation landscape and altered L3mbtl2-mediated transcriptional activity in cancer-associated muscle contractile dysfunction. (n.d.). https://doi.org/10.1038/s41420-026-03337-y

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03337-y

Keywords: SUMOylation, L3mbtl2, cancer cachexia, skeletal muscle, contractile dysfunction, transcriptional regulation, chromatin, post-translational modification, muscle wasting, epigenetics, oncology, Cell Death & Discovery

The research team set out to answer a deceptively simple question: when prostate cancer cells stop responding to enzalutamide, what has actually changed inside them? Resistance is often described in terms of genetic mutations in the androgen receptor or amplification of the receptor gene itself, but these alterations explain only a fraction of clinical cases. Increasingly, cancer biologists have recognized that drug-tolerant cells frequently survive by adjusting their metabolism, the network of chemical reactions that converts nutrients into energy, building blocks and signaling molecules. Because metabolic rewiring is a physical requirement for survival rather than an optional accessory, it may represent a more universal and more druggable hallmark of resistance than any single mutation.

To capture that rewiring comprehensively, the investigators applied a multi-omic pipeline to paired models of enzalutamide-sensitive and enzalutamide-resistant prostate cancer cells. Transcriptomic sequencing revealed which genes were switched on or off; proteomic mass spectrometry quantified the enzymes actually present in the cells; and metabolomic profiling measured the small molecules, sugars, amino acids and lipids that flow through the metabolic network. The power of this approach lies in its convergence. A change in a single data type can be misleading, but when altered messenger RNA, altered protein and altered metabolite levels all point to the same pathway, the evidence becomes difficult to dismiss.

The analysis converged on several interconnected metabolic shifts. Resistant cells displayed a marked reorganization of lipid metabolism, upregulating pathways for fatty acid synthesis and elongation while also altering cholesterol handling. This makes biological sense for prostate cancer in particular, because the androgen receptor does more than respond to testosterone; it also regulates genes involved in lipid acquisition and synthesis, and membrane lipid composition influences receptor signaling at the cell surface. By boosting de novo lipogenesis, resistant cells appear to buffer themselves against the loss of androgen-driven lipid programs that enzalutamide imposes, effectively rebuilding a supply line the drug was designed to cut.

Energy metabolism showed equally telling changes. Profiling of central carbon metabolism indicated that resistant cells leaned more heavily on glycolysis and on glutamine-fueled anaplerosis, the process by which the amino acid glutamine tops up the tricarboxylic acid cycle with carbon. Mitochondrial oxidative phosphorylation was also reconfigured, with altered expression of electron transport chain components suggesting a shift in how resistant cells balance ATP production against the generation of biosynthetic precursors. These are not idle adjustments. Rapidly dividing tumor cells must simultaneously produce energy, reduce cellular building blocks and maintain antioxidant defenses, and the observed pattern is characteristic of cells that have traded metabolic efficiency for metabolic flexibility.

Crucially, the study did not stop at description. The researchers tested whether the metabolic alterations they detected could be exploited therapeutically. Inhibiting key enzymes in the upregulated lipid synthesis pathway reduced the viability of enzalutamide-resistant cells more severely than that of their drug-sensitive counterparts, indicating a genuine dependence rather than incidental correlation. Similar experiments targeting glutamine metabolism and mitochondrial respiration produced the same pattern of selective vulnerability. When metabolic inhibitors were combined with continued enzalutamide treatment, the effect was additive, and in some settings synergistic, meaning that the resistant cells could be resensitized to the drug they had learned to ignore.

The concept underlying these results is known as collateral vulnerability. When cancer cells evolve resistance to one pressure, the evolutionary path they take often creates new dependencies that did not exist before. A cell that ramps up fatty acid synthesis to survive androgen receptor blockade, for example, becomes exquisitely sensitive to inhibitors of that synthesis pathway. Because these dependencies are consequences of the resistance program itself, they are less likely to be bypassed by further tumor evolution without a significant fitness cost. This is the same logic that has made synthetic lethal strategies, such as PARP inhibition in DNA repair-deficient tumors, one of the most productive ideas in modern oncology, now extended into the metabolic arena.

The findings carry practical implications for the clinic. Enzalutamide resistance currently marks a transition point at which patients move toward chemotherapy, androgen biosynthesis inhibitors or, for those with suitable tumor biology, radioligand therapy. If metabolic vulnerabilities of the kind identified here can be confirmed in patient-derived models and ultimately in clinical trials, metabolic inhibitors could be layered onto existing regimens at the first sign of rising prostate-specific antigen during enzalutamide treatment, potentially delaying or preventing overt resistance. The study also raises the possibility of using metabolic imaging or circulating metabolite profiles as biomarkers, allowing clinicians to detect the metabolic shift before the tumor has fully escaped hormonal control.

Several caveats temper the enthusiasm. Cell line models, even well-characterized ones, capture only part of the complexity of human tumors, which contain stromal cells, immune infiltrates, variable oxygen and nutrient availability and extensive intratumoral heterogeneity. Metabolic phenotypes are notoriously context-dependent, shaped by the culture conditions in which cells are grown and by the specific evolutionary path each resistant line has taken. The authors’ use of multiple paired models and convergent multi-omic evidence strengthens their conclusions, but translating these dependencies into patients will require validation in organoids, xenografts and ultimately biopsy material from men whose disease has progressed on enzalutamide. Dose-limiting toxicities of metabolic inhibitors, particularly those affecting normal tissues with high metabolic flux, will also need careful management.

Nevertheless, the study represents a meaningful step toward a more complete picture of how prostate cancer defeats one of its most important therapies. By treating metabolism not as background housekeeping but as a central player in drug resistance, and by interrogating that metabolism with layers of molecular data rather than single measurements, the work provides both a mechanistic map and a practical target list. For the growing population of men living with castration-resistant prostate cancer, the hope is that the very adaptations tumors use to survive enzalutamide will become the handles by which the next generation of treatments pulls them back into vulnerability.

Subject of Research: Metabolic rewiring in enzalutamide-resistant prostate cancer identified through integrated transcriptomic, proteomic and metabolomic profiling

Article Title: Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer

Article References: Lee, O., Fidelito, G., Zhao, Q., Liu, B., Choi, H., Taylor, R. A., & Watt, M. J. (2026). Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03332-3

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03332-3

Keywords: prostate cancer, enzalutamide, drug resistance, multi-omics, metabolism, lipid metabolism, glutamine, androgen receptor, oxidative phosphorylation, collateral vulnerability, cancer therapeutics, Cell Death Discovery